Anti-CTLA-4 therapy results in higher CD4(+)ICOS(hi) T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Cytotoxic lymphocyte antigen-4 (CTLA-4) blockade is an active immunotherapeutic strategy that is currently in clinical trials in cancer. There are several ongoing trials of anti-CTLA-4 in the metastatic setting of prostate cancer patients with reported clinical responses consisting of decreases in t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Chen, Hong, Liakou, Chrysoula I., Kamat, Ashish, Pettaway, Curtis, Ward, John F., Tang, Derek Ng, Sun, Jingjing, Jungbluth, Achim A., Troncoso, Patricia, Logothetis, Christopher, Sharma, Padmanee
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2009
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2650334/
https://ncbi.nlm.nih.gov/pubmed/19202079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0813175106
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller